Ironwood and Bionomics Sign Compound Agreement

The companies will collaborate on initial research and Ironwood will be responsible for worldwide development and commercialization of all products incorporating BNC210 or other licensed compounds.

Ironwood Pharmaceuticals, Inc. and Bionomics Limited announced Wednesday that they have inked a collaboration, research, and licensing deal that will enable Ironwood to develop and commercialize Bionomics' investigational anti-anxiety compound BNC210 and other related compounds.

The goal of the collaboration is to evaluate the compound's potential as a novel anti-anxiety treatment.

Data from several preclinical studies indicate that BNC210 has anti-anxiety activity without the sedative side effects that are typical of benzodiazepines, a class of drugs used to treat anxiety. These data are further strengthened by Phase 1 clinical studies, where pharmacodynamic markers of anti-anxiety activity without sedation were observed in healthy